AXS Investments’s iShares Biotechnology ETF IBB Stock Holding History

AXS Investments’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,000	Closed	-$889K	–	426
2023 Q2	$889K	Buy	+7,000	New	+$909K	0.24%	158

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AXS Investments's IBB Position: Q3 2023 in Review

AXS Investments sold out of iShares Biotechnology ETF (IBB) in Q3 2023, closing a stake of 7,000 shares — an estimated $889K sold.

AXS Investments first reported a position in IBB in Q2 2023 and held it in 1 quarter. The position peaked at $889K in Q2 2023. 832 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

AXS Investments reported no remaining iShares Biotechnology ETF position as of Q3 2023 after selling out during the quarter.
AXS Investments sold 7,000 iShares Biotechnology ETF shares in Q3 2023, an estimated $889K.
AXS Investments first reported a position in iShares Biotechnology ETF in Q2 2023 and held it in 1 quarter.
AXS Investments's iShares Biotechnology ETF position peaked at $889K in Q2 2023.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on AXS Investments's 13F filing for Q3 2023, filed 9 Nov 2023.